2017年 · 第97卷第45期

Alzheimer's disease (AD) is the most common type of senile dementia. It is a progressive central nervous system degenerative disease. The main clinical manifestations are comprehensive decline of cognitive function, accompanied by abnormal personality and mental behavior, and final loss of daily life ability. The World Health Organization (WHO) estimates that the prevalence of AD in the global population over 65 years old is 4% to 7%, and in the elderly population over 85 years old, the prevalence of AD can be as high as 20% to 30%. It is estimated that there will be more than 80 million patients with AD worldwide by 2040. AD not only brings great pain to patients, but also brings heavy mental pressure and medical and care burden to families and society. It has become a social public health problem that cannot be ignored. Therefore, the research on AD has become one of the hot spots in the research of senile degenerative diseases.

The 6-year-old child was transferred to the Department of Pediatrics of Zhengzhou People's Hospital on January 21, 2017 due to "fever, cough for 17 days, vomiting, abdominal pain for 5 days, unsteady walking and drowsiness for 3 days". Usually prone to "respiratory infections". 17 days ago, after catching a cold, he had fever and cough, and the highest body temperature was unknown. He was proposed to be diagnosed with lobar pneumonia, and the treatment effect of drugs such as "azithromycin and cephalosporin antibiotics" was not good. He was transferred to the municipal children's hospital and performed fiberoptic bronchoscopy. He was given "cefotaxime" treatment and the fever stopped. After 5 days of greasy food, abdominal pain and vomiting occurred, accompanied by fatigue, inability to stand, lethargy, and poor treatment effect. 3 days ago, I had instability in sitting, standing and walking, drowsiness, inability to sit up from the recumbent position, no diplopia and blurred vision.

Modern anti-cancer therapy has significantly reduced the mortality of cancer patients, but its cardiovascular toxicity has become the main determinant of patient prognosis. According to the particularity of cancer patients, a new discipline-onco-cardiology or cardio-oncology has emerged. Because large randomized clinical trials mostly exclude cancer patients, little information is available on this population. In order to guide the clinical treatment of this group, expert consensus has recently been issued in Europe and the United States^[1]Position Statement^[2]And guidelines^[3,4]。 This article mainly introduces the evaluation and management of chemotherapy-induced coronary artery toxicity.

Quality of life, as defined by the World Health Organization, is a multidimensional construction of an individual's perception of their position in life in the context of culture and values, in relation to the individual's goals, expectations, standards and concerns. Individual physical health, mental state, degree of independence, social relations, personal beliefs and their relationship with the distinctive characteristics of the environment, etc., affect the quality of life in complex ways^[1]。 Endometriosis (hereinafter referred to as endometriosis) is one of the most common benign gynecological diseases, affecting approximately 10% of women during the reproductive period. The negative impact on the patient's physique, mental psychology and social function leads to problems in all areas of life, including career, personal relationships, sexual life, social and family relationships, etc. The study of quality of life related to endometriosis not only has guiding value for diagnosis and treatment, but also is an important topic related to health economics. In prospective multicenter studies, the economic loss caused by endometriosis was similar to that of other chronic diseases (such as diabetes, Crohn's disease and rheumatoid arthritis)^[2,3], disruption and decline in quality of life levels are predictors of endometriosis-related economic losses. The research on quality of life related to endometriosis has received more attention in recent 10 years, and there were few relevant reports and analyses before 2006.

Globally, liver cancer is one of the malignancies causing a serious disease burden, with the sixth highest incidence and second highest mortality among all malignancies. Its incidence has regional characteristics, with East Asia and Africa as high-incidence areas. In 2012, Chinese patients accounted for 50% of new liver cancer cases worldwide^[1]。 Among primary liver carcinomas, hepatocellular carcinoma accounts for the vast majority. However, Chinese patients with hepatocellular carcinoma have obvious characteristics in terms of demography, risk factors and clinical stage. A total of 18 031 patients with hepatocellular carcinoma from 14 countries were included in a global large retrospective cohort study (BRIDGE study). Among them, 8 683 patients in mainland China were at a young age of onset, had a high rate of hepatitis B virus (HBV) infection (77%), and had a late tumor stage (58% of patients were advanced and terminal at the time of diagnosis).^[2]。 Therefore, there are certain particularities in the comprehensive management of hepatocellular carcinoma patients in China.